Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease

Diabetes, Obesity and Metabolism

Volumn 18, Issue 8, 2016, Pages 766-774

  Leiter, L A ^a   Cefalu, W T ^b   de Bruin, T W A ^c   Xu, J ^c   Parikh, S ^c   Johnsson, E ^d   Gause Nilsson, I ^d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

cardiovascular disease; dapagliflozin; sodium glucose co transporter 2 inhibitor; type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; ANGINA PECTORIS; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CYSTITIS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RIGHT BUNDLE BRANCH BLOCK; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROSTATITIS; SHOCK; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; WEIGHT REDUCTION; AGED; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; HYPOVOLEMIA; LONGITUDINAL STUDY; MAINTENANCE CHEMOTHERAPY; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC);

AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; HYPOVOLEMIA; LONGITUDINAL STUDIES; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; URINARY TRACT INFECTIONS;

EID: 84969784577     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12666     Document Type: Article

References (45)

1. Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes 2013; 6: 327–338.
2. Fox CS, Coady S, Sorlie PD et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292: 2495–2499.
3. Wilson PW. Diabetes mellitus and coronary heart disease. Endocrinol Metab Clin North Am 2001; 30: 857–881.
4. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720.
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
6. Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease. Diabet Med 1997; 14(Suppl. 3): S25–31.
7. Gerstein HC. The plasma glucose level-a continuous risk factor for vascular disease in both diabetic and non-diabetic people. Adv Exp Med Biol 2001; 498: 35–39.
8. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–431.
9. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008–2017.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
11. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429–442.
12. Farxiga [prescribing information]. AstraZeneca Pharmaceuticals LP, Wilmington, DE, 2015.
13. European Medicines Agency. Forxiga summary of product characteristics. 2015. Available from URL: http://ec.europa.eu/health/documents/community-register/2012/20121112124487/anx_124487_en.pdf. Accessed 31 July 2015.
14. Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med 2015; 32: 531–541.
15. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014; 16: 124–136.
16. Nauck MA, Del PS, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015–2022.
17. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510–516.
18. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650–657.
19. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 2015; 38: 1218–1227.
20. Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 2014; 62: 1252–1262.
21. Del Prato S, Nauck M, Duran-Garcia S et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in type 2 diabetes patients: 4-year data. Diabetes Obes Metab 2015; 17: 581–590.
22. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217–2224.
23. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014; 37: 740–750.
24. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853–862.
25. Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014; 5: 267–283.
26. American Diabetes Association. Standards of medical care in diabetes—2015. www.diabetes.org/diabetescare. 2015. Available from URL: http://diabetes.teithe.gr/UsersFiles/entypa/STANDARDS%20OF%20MEDICAL%20CARE%20IN%20DIABETES%202015.pdf. Accessed 10 September 2015.
27. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020–1031.
28. Cefalu W, Leiter L, Johnsson E, Sugg J, Gause-Nilsson I. Safety and efficacy of dapagliflozin in patients with T2DM and cardiovascular disease receiving loop diuretics. Presented at American Diabetes Association (ADA) 75th Annual Scientific Session, Boston, 5–9 June 2015. Poster 1216-P.
29. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162.
30. Einarson TR, Garg M, Kaur V, Hemels ME. Composite endpoints in trials of type-2 diabetes. Diabetes Obes Metab 2014; 16: 492–499.
31. Clinicaltrials.gov. A pragmatic trial to evaluate the comparative effectiveness between dapagliflozin and standard of care in type 2 diabetes patients (DECIDE Study). Study NCT02616666, 10 February 2016. Available from URL: https://clinicaltrials.gov/ct2/show/NCT02616666. Accessed 17 February 2016.
32. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. EMA Website; May 2012. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed 1 February 2016.
33. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US FDA Website; December 2008. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 1 February 2016.
34. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
35. Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262–274.
36. Langkilde AM, Johansson P, Ptaszynska A, Johnsson E. Cardiovascular safety of the SGLT2 inhibitor dapagliflozin: meta-analysis with >6000 patient years exposure. Presented at: American Heart Association (AHA) 2013 Scientific Sessions, Dallas, 16–20 November 2013. Abstract 11105.
37. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016; 15: 37.
38. Clinicaltrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE TIMI-58). Study NCT01730534, 10 December 2015. Available from URL: https://clinicaltrials.gov/ct2/show/NCT01730534. Accessed 17 February 2016.
39. Walz L, Pettersson B, Rosenqvist U, Deleskog A, Journath G, Wandell P. Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes. Patient Prefer Adherence 2014; 8: 593–601.
40. Arnold LW, Wang Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud 2014; 11: 138–152.
41. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009; 54: 422–428.
42. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687–1693.
43. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: 1638–1642.
44. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015; 38: 1680–1686.
45. Andersson Sundell K, Sonesson C, Shoetan N, Fredriksson M, Johnsson E. Occurrence of diabetic ketoacidosis among type 2 diabetes patients in Humedica/Optum observational data and in dapagliflozin clinical trials. Presented at Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) 5th Annual World Congress, Istanbul, 5–7 2015. Abstract 28.